Method and system for treatment of atrial tachyarrhythmias

Information

  • Patent Grant
  • 8512337
  • Patent Number
    8,512,337
  • Date Filed
    Friday, August 20, 2004
    19 years ago
  • Date Issued
    Tuesday, August 20, 2013
    10 years ago
Abstract
A method of and a system for treatment of atrial tachyarrhythmias. The system includes a set of hemostats having elongated opposing jaws carrying mechanisms for applying ablation energy along the jaws. The jaws having straight and curved configurations selected to allow arrangement of the jaws of along opposite sides of walls of a patient's atrium. Treatment is accomplished by applying of ablation energy to the walls of a patient's artria to create lines of lesion corresponding generally to incisions employed in a Maze type procedure.
Description
BACKGROUND OF THE INVENTION

The present invention relates to surgical tools and procedures generally and relates more particularly to the use of electrosurgical ablation to treat atrial fibrillation.


In patients with chronic atrial fibrillation having tachycardia that resistant to medical treatment, the Maze III procedure has been employed. This procedure controls propagation of the depolarization wavefronts in the right and left atria by means of surgical incisions through the walls of the right and left atria. The incisions create blind or dead end conduction pathways, which prevent re-entrant atrial tachycardias from occurring. While the Maze procedure is successful in treating atrial fibrillation, the procedure is quite complex and is currently practiced by only a few very skilled cardiac surgeons in conjunction with other open-heart procedures. The procedure also is quite traumatic to the heart, as in essence the right and left atria are cut into pieces and sewed back together, to define lines of lesion across which the depolarization wavefronts will not propagate.


It has been suggested that procedures similar to the Maze procedure could be instead performed by means of electrosurgical ablation, for example, by applying RF energy to internal or external surfaces of the atria to create lesions across which the depolarization wavefronts will not propagate. Such procedures are disclosed in U.S. Pat. No. 5,895,417, issued to Pomeranz, et al., U.S. Pat. No. 5,575,766, issued to Swartz, et al., U.S. Pat. No. 6,032,077, issued to Pomeranz, U.S. Pat. No. 6,142,944, issued to Swanson, et al. and U.S. Pat. No. 5,871,523, issued to Fleischman, et al, all incorporated herein by reference in their entireties. Hemostat type electrosurgical or cryo-ablation devices for use in performing such procedures are described in U.S. Pat. No. 5,733,280 issued to Avitall, U.S. Pat. No. 6,237,605 issued to Vaska, et al, U.S. Pat. No. 6,161,543, issued to Cox, et al., PCT published Application No. WO99/59486, by Wang and in pending U.S. patent application Ser. No. 09/747,609 filed Dec. 22, 2000 by Hooven, et al., all incorporated herein by reference in their entireties. In order for such procedures to be effective it is desirable that the electrosurgically created lesions are continuous along their length and extend completely through the tissue of the heart. These goals may be difficult to accomplish employing dry ablation electrodes or electrodes applied only to the interior or exterior surfaces of the heart tissue.


SUMMARY OF THE INVENTION

According to the present invention, a maze type procedure may be performed using a set of bipolar electrosurgical hemostats, which apply ablation energy (e.g. RF energy) across the walls of the left and right atria by means of delivery means (e.g. electrodes) located on either side of the atrial walls. In a preferred embodiment of the invention, the hemostats are provided with elongated RF electrodes having various straight and curved configurations. In the particular embodiment of the invention described herein, a collection of straight and curved bipolar electrosurgical hemostats is provided in order to allow the physician to produce lines of lesion that approximate the incisions that would occur during the Maze III procedure as described in the book ‘Cardiac Surgery Operative Technique’ by Donald B. Doty, M. D. at pages 410-419, incorporated herein by reference in its entirety, and hereafter referred to as the “Doty reference”. Other specific sets of hemostats may correspondingly be provided according to the invention to allow approximation of lines of lesion of the incisions that would be provided by other forms of the Maze procedure.


The invention as disclosed herein is describing the context of an open chest surgery, with patient undergoing cardiopulmonary bypass. As described, the procedure does include a limited number of surgical incisions, in conjunction with the creation of various straight and curved lesions using the bipolar electrosurgical hemostat set of the present invention. However, the present invention is also believed applicable to closed chest procedures, in which the heart is observed thoracoscopically and access is provided by means of thoracoscopic surgical ports. It is believed that ultimately, the invention may also applicable to closed chest, beating heart surgery, dispensing with the necessity of cardiac bypass.





A BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A illustrates a first embodiment of an electrosurgical hemostat according to the present invention having two elongated generally straight jaws.



FIG. 1B illustrates an alternative configuration for the tips of the jaws of the hemostat illustrated in FIG. 1A.



FIGS. 2A, 2B, 2C and 2D all illustrate cross section through alternative configurations for electrodes carried by the jaws of the hemostat illustrated in FIG. 1A.



FIGS. 3A and 3B illustrate top and side views of a second electrosurgical hemostat according to the present invention.



FIGS. 4A and 4B illustrate top and side views of a third electrosurgical hemostat according to the present invention.



FIGS. 5A and 5B illustrate top and side views of a fourth electrosurgical hemostat according to the present invention.



FIGS. 6A through 6M are a series of drawings illustrating schematically the surgical procedure performed using the electrosurgical hemostats of the present invention and illustrating schematically the various incisions and lesions produced according to the present invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention as disclosed in the present application includes a set of four pre-configured straight and curved hemostats, particularly optimized for performing an electrosurgical procedure mimicking the incisions provided according to Maze III surgical procedure. The set of hemostats is described in more detail below.



FIG. 1A illustrates a top plan view of the first of the four hemostats provided to the present invention. The hemostat may be approximately 31 centimeters in overall length as illustrated at B2, with draws of approximately 8 centimeters in length, as illustrated at A1.


The hemostat includes two elongated handle members 12 and 14, each provided with a finger loop at its proximal end. A conventional hemostat locking mechanism 14 is also provided. The handles of the hemostat may be fabricated of stainless steel or other readily resterilizable material. Alternatively, the handles 11 and 12 might be fabricated of a biocompatible plastic and/or the hemostat may be disposable.


To the jaws 18 and 19 of the hemostat extend distally from the pivot or hinge 16, and carry elongated electrosurgical electrodes 24 and 25. When the jaws are parallel to one another, electrodes 25 and 25 are preferably spaced approximately 0 to 7 mm from one another, more preferably 1 to 5 mm from one another, to facilitate uniform contact allng opposite sides of a patient's atrial wall. In use, the atrial wall is compressed between electrodes 24 and 25, and R-F energy is applied between the electrodes in order to create an elongated continuous lesion extending through the cardiac tissue. Using the hemostat of FIG. 1A, a linear lesion is produced.


The electrodes 24 and 25 are preferably configured to allow fluid-assisted tissue ablation, of the type generally described in U.S. Pat. No. 6,096,037, U.S. Pat. No. Mulier, incorporated herein by reference in its entirety. To this end, each of the electrodes is provided with an electrical conductor, 20, 23 allowing delivery of R-F electrical energy to the electrodes 24 and 25, respectively and with a fluid lumen 21, 22 allowing for delivery of saline solution or other conductive fluid to and along the length of electrodes 24 and 25. Various alternative embodiments of the electrodes and jaws of the hemostat of FIG. 1A are illustrated in FIGS. 2A through 2D, discussed below.


In use in a preferred embodiment of the invention, one jaw of the hemostat of FIG. 1A is inserted into the interior right or left atrium through an incision provided in the wall of the left or right atrium, while the other jaw remains outside of that chamber. The jaws are pressed together, somewhat compressing the atrial wall between the jaws, to provide for continuous contact along the length of the jaws on both sides of the atrial wall. RF energy is delivered between the electrodes. Control of delivery of energy or power to assure a complete lesion may be accomplished by measurement of impedance between the electrodes, as in U.S. Pat. No. 6,133,592, issued to Taylor, U.S. Pat. No. 5,718,701, issued to Shai, et al or U.S. Pat. No. 5,357,956, issued to Nardella, or allowed Pending U.S. application Ser. No. 09/347,635, filed Jul. 6, 1999 by Hoey et al, all incorporated herein by reference in their entireties. Alternatively, thermocouples or other temperature sensors may be added to the jaws of the hemostat and delivery of energy or power controlled as in U.S. Pat. No. 5,685,878, issued to—Falwell, et al., U.S. Pat. No. 6,045,550, issued to Simpson, et al., U.S. Pat. No. 5,688,267, issued to Panescu, et al or U.S. Pat. No. 5,596,995, issued to Sherman, et al., all also incorporated herein by reference in their entireties. As an additional alternative, delivery of energy or power may be time terminated, based upon empirically determined times found to lesions extending completely through the atrial walls at the power or energy levels chosen, or regulation of ablation energy by means of any of the references cited above may be employed if appropriate.


It is anticipated that in some versions of the present invention which employ a more limited access approach to the heart, the distal tips of hemostat jaws themselves may be sharpened and used to pierce the atrial wall, eliminating the necessity of a separate incision. FIG. 1B illustrates such an alternative hemostat jaw construction, wherein hemostat jaws 18A and 19A correspond generally to jaws 18 and 19 in FIG. 1A, and carry electrodes 24A and 25A which also correspond to electrodes 24 and 25 in FIG. 1A. However, the distal tips 15 and 17 of the jaws are sharpened to a point or an edge so that either may be used to directly penetrate the atrial wall, eliminating the necessity of a separate incision.



FIGS. 2A through 2D are cross sectional views through the jaws of a hemostats as in FIG. 1A, illustrating possible alternative constructions. In FIG. 2A, the jaws 18 and 19 are made of a metallic core 26, 28, covered by an insulative coating or paint, 27, 29. Electrodes 24 and 25 take the form of elongated conductive coils, 30A, 33A, carrying tubes 31A, 32A, of expanded PTFE, through which a conducted fluid such as saline solution may be delivered along the length of the electrode coils 30A, 33A. The lumens of the EPTFE tubes 31A, 32A may be sealed at their distal extremities.



FIG. 2B illustrates a first alternative embodiment, corresponding generally to that illustrated in FIG. 2A, with elements corresponding to those identically numbered in in FIG. 2A. In this embodiment, the configuration of the conductive coil, 31B, 32B and the expanded PTFE tubes, 32B, 33B is reversed, so that the coils are located within the EPTFE tubes. As in the embodiment illustrated in Figure A, saline or other conductive fluid is delivered through the inner lumen of EPTFE tubes 32B, 33B.



FIG. 2C illustrates a third embodiment according to the present invention. In this case, elements also correspond to identically numbered elements in FIG. 2A. However, in the embodiment of FIG. 2C, elongated guides or flanges 35 are added in order to enhance longitudinal alignment of the jaws 18 and 19, along their length. When heart wall tissue is compressed between jaws 18 and 19, flanges 35 tend to retain jaws 18 and 19 and correspondingly electrode coils 30A and 33A in alignment with one another, through the intermediary of the atrial wall tissue.



FIG. 2D illustrates a fourth embodiment, corresponding generally to that illustrated in FIG. 2B, discussed above. Elements correspond to identically numbered elements in FIG. 2B. In addition, jaws 18 and 19 are each provided with elongated magnetic elements 37, arranged to assist in pulling jaws 18 and 19 toward one another when the jaws are closed around atrial wall tissue. Elements 37 may be formed of rare earth magnets, so that their mutual attraction provides additional compressive force along the length of jaws 18 and 19, enhancing contact with atrial wall tissue. In the case of embodiments in which the cross sectional size of jaws 18 and 19 is reduced in order to facilitate insertion into tight spaces, inclusion of magnets 37 is believed particularly valuable. The inclusion of magnets 37 is also believed particularly valuable in embodiments in which jaws 18 and 19 are fabricated of a less rigid material, for example a somewhat flexible plastic as opposed to a rigid metal such as stainless steel.


It should be understood that the above-described cross sectional illustrations of the configurations of the jaws of the hemostat of FIG. 1A also apply to the construction of the jaws of the other three hemostats discussed below in conjunction with the present invention. The spacing between the electrodes on the jaws of these hemostats should also be understood to correspond to that of the hemostat of FIG. 1A. As such, electrode configurations for the hemostats of FIGS. 3A-5B are not discussed separately herein. Similarly, while conductors and fluid lumens are not illustrated in FIGS. 3A-5B, they should be understood to be present and correspond to those as illustrated in FIG. 1A. In addition, sharpened jaw tips as illustrated in FIG. 1B may also be employed.



FIGS. 3A and 3B illustrate top and side views, respectively, of a second hemostat according to the present invention. In this case, the hemostat is provided with first and second handle portions 111 and 112, which correspond to handles 11 and 12 of the hemostat illustrated in FIG. 1A, and is also likewise provided with a locking mechanism 114. The jaws 118 and 119 correspond generally in structure to the jaws 18 and 19 of the hemostat of FIG. 1, however, in this case, the jaws 118 and 119 are bent to describe a generally straight distal portion extending over a length E2, which may be, for example, 5½ centimeters. The jaws are bent at C2 around a radius of approximately 0.5 centimeters and describe an angle D2 of approximately 60 degrees, as illustrated. The overall length of the hemostat B2 may be, for example, 23 centimeters, with the overall length of the jaws as illustrated at A2 being, for example, about 6½ centimeters from pivot 116 to the distal ends of the hemostat jaws, as measured in the plane defined by the handle members 111 and 112.



FIGS. 4A and 4B similarly illustrate top and side views of a third hemostat according to the present invention. Like the previous hemostats, this hemostat is provided with handled portions 211 and 212 and a conventional locking mechanism 214. Like the hemostat illustrated in FIGS. 3A and 3B, jaws 219 and 219 of this hemostat are similarly bent out of the plane defined by the two handled portions 211 and 212. In this case, the jaws 218 and 219 are bent to define a distal, generally straight portion E3 extending for approximately 2 centimeters, and are bent around a radius C3 of approximately 3 centimeters, to define an angle D3 of approximately 65 degrees. The overall length of the hemostat as measured in the plane defined by the handles 211 and 212 is approximately 26 centimeters, and the length of A3 of the jaws, as measured along the plane defined by the handles 211 and 212 is approximately 6 centimeters.



FIGS. 5A and 5B illustrate a fourth hemostat according to the present invention. Like the other hemostats, it is provided with handled portions 311 and 312 and a locking mechanism 314. This hemostat also displays a curved configuration, with jaws 318 and 319 bent upward out of plane defined by the handled portions 311 and 312, to define a generally straight distal portion extending over a length E4 of approximately 3 centimeters, and around a radius C4 of approximately 5 centimeters to define an angle D5 of approximately 60 degrees. As measured along the plane defined by handle 311 and 312, the overall length B4 of the hemostat is approximately 29 centimeters and the length A4 of the jaws extending from hinge 316 to the distal tips of jaws is approximately 9 centimeters.



FIGS. 6A-6M are schematic drawings which illustrate a procedure performed using the bipolar electrosurgical hemostats described above to obtain a result analogous to the Maze III procedure as described in the Doty reference cited above. The lines of lesion produced using the hemostats correspond to incisions as described in this reference, and the correspondence of the lesions to the incisions is described below.



FIG. 6A is a schematic drawing illustrating the structure of the right and left atria, 500, 502, respectively, as viewed from a lower aspect, including tricuspid valve 16 and mitral valve 14 and as viewed from a more superior aspect, including the bases of the pulmonary veins 512 and the bases of the superior vena cava and inferior vena cava, 508 and 510 respectively, which enter the right atrium 500. The right and left atrial appendages are also illustrated schematically at 504 and 506, respectively. The structures as illustrated in FIG. 6A are correspondingly numbered in FIGS. 6B through 6M below.


For purposes of understanding the basic method of the present invention as illustrated, it should be assumed that the operation is undertaken as an open chest operation, with the heart stopped and the patient on full bypass. Modifications to the procedure, in case of a limited access, stopped heart procedure and/or a limited access, beating heart procedure, are also generally described. FIG. 6B illustrates the first step of the procedure, comprising removal of the right atrial appendage 504. Right atrial appendage 504 is removed by means of an incision 507, which may be made by means of a scalpel or scissors. In a context of a closed chest procedure on either a beating or a stopped heart, a thoracoscopic tool may be substituted, preferably one capable of simultaneously cutting and stapling the remnant of the right atrial appendage.



FIG. 6C illustrates the second step of the procedure, as performed using an open chest approach. During the second step, the electrosurgical hemostat of FIG. 1A is employed, with one jaw (19) of the hemostat inserted into the right atrium through the opening left by removal of the right atrial appendage and the other jaw arranged along the exterior surface of the heart. Jaws 18 and 19 are inserted until they extend to a point 520 located approximately at the mid point of the right atrium, approximately 5 centimeters from the opening 505 left by removal of the right atrial appendage. The jaws 18 and 19 are compressed and RF energy is applied between the electrodes located in jaws 18 and 19 to create an elongated lesion, extending through the tissue of the right atrial wall, to provide a block against passage of depolarization waves. For purposes of the following drawings, the placement of various hemostats will be described, but not specifically illustrated. Instead, the lesions to be produced by the hemostats will be illustrated by means of beaded lines, so that their interconnection and their relationship to the structures of the left and right atria 502, 500, may be understood. It should be understood that the hemostats are to be placed with their jaws extending along the lines of lesion as illustrated, unless otherwise specified.


In closed chest, limited access procedures, it is anticipated that the lesion produced may be made by inserting the jaw of an electrosurgical hemostat as illustrated in conjunction FIG. 1A, but having a sharpened tip as illustrated in FIG. 1B, directly through the heart wall at point 520, and the jaws advanced to the sealed remnant of the removal of the right atrial appendage to define a corresponding lesion.



FIG. 6D illustrates the next step in the procedure and also illustrates lesion 522 produced by the application of the electrosurgical hemostat as illustrated in FIG. 6C. Lesion 522 corresponds generally to the incision illustrated at step A1 as described in the Doty reference. At 524, a local access incision is cut, at a point approximately midway between the inferior vena cava and superior vena cava (510, 508). Lesions 526 and 528, extending from access incision 524 to the superior and inferior vena cava, respectively, are produced by inserting one jaw of a hemostat as illustrated in FIG. 1A through the access incision 524 and arranging the jaws of the hemostat to extend on either side of atrial tissue from the incision 524 to the superior vena cava and inferior vena cava, respectively. Alternatively, a hemostat as illustrated in FIGS. 3A and 3B might be employed, with atrial tissue compressed between the straight, distal portions of the jaws. The lesions 528 and 526 so produced correspond to the incisions illustrated at step B as described in the Doty reference. In more limited access surgeries, hemostats having sharpened jaws as illustrated in FIG. 1B might be employed, with the sharpened tip of a jaw employed to create the access incision 524.



FIG. 6E illustrates the next step in the procedure. In this step, one jaw of a hemostat as illustrated in FIG. 1A or as illustrated in FIGS. 3A and 3B is inserted through access incision 524, and the jaws are arranged along either side of the atrial wall to create lesion 530, extending to the annulus of tricuspid valve 516, terminating at a point 534 approximately at the center of the posterior leaflet 532. This lesion should extend as close as possible to the tricuspid annulus. This lesion corresponds generally to the incision illustrated at steps D and E as described in the Doty reference. Optionally, cryo-ablation may be performed to complete the lesion at the tricuspid annulus at the terminus of lesion 530, by means of a cryo-probe inserted through the opening 505 in the remnant of the right atrial appendage. Cryo-ablation corresponds generally to that illustrated at step F as described in the Doty reference. In more limited access surgeries, the cryo-probe might be inserted through access lesion 524 or might be inserted transvenously.



FIG. 6F illustrates the next step of the procedure. In FIG. 6F, lesion 536 is created using the distal portion of the jaws of a hemostat as in FIG. 1A. One jaw of the hemostat is inserted through the opening 505 in the remnant of the right atrial appendage, and the jaws are arranged to extend along either the right atrial wall to the annulus of the tricuspid valve 516 at the midpoint of the anterior leaflet 538. This lesion corresponds generally to the incision illustrated at steps H and I as described in the Doty reference. Care must be taken during this step to avoid the right coronary artery. Optionally, cryo-ablation may be applied at the tricuspid annulus at point 540, at the termination of lesion 536. Again, cryo-ablation may be provided by means of a cryo-probe inserted via the opening 505 in the remnant of the right atrial appendage, through access lesion 524, or, alternatively be means of a cryo-probe inserted transvenously. Cryo-ablation corresponds generally to that illustrated at step J as described in the Doty reference.



FIG. 6G illustrates the next step of the procedure which is the creation of an incision 542 extending through the left atrial wall, posterior to the inter atrial groove, near the orifices of the right pulmonary veins. In an open chest procedure, incision 542 may be made conventionally by means of scissors or a scalpel. Incision 542 corresponds to the incision illustrated at step K as described in the Doty reference. In more limited access surgeries, incision 542 might be replaced by a simple access incision made by means of the sharpened tip of one of the jaws of the hemostats used to create the lesions surrounding the orifices of the pulmonary veins, as discussed below.



FIG. 6H illustrates the next step of the procedure, which is the creation of lesions 543 and 546. Lesions 543 and 546 may be accomplished by insertion of a hemostat having curved jaws as illustrated in FIGS. 5A and 5B, reversing the orientation of the hemostat between lesions, to create lesions extending around the base of the pulmonary veins 512 and meeting at a point 544, to complete the line of lesion. Incision 542 completes the line of lesion encircling the bases of the pulmonary veins. Lesions 543 and 546 correspond generally to the incisions illustrated at steps L and N as described in the Doty reference. In an alternative procedure, Lesions approximating the incisions illustrated at steps L and N may be produced by compressing the atrial wall tissue adjacent the bases of the left pulmonary veins between jaws of the hemostat illustrated in FIG. 4A or 5A applied epicardially to produce a lesion encircling the bases of the left pulmonary veins and repeating the procedure to correspondingly produce a lesion encircling the bases of the right pulmonary veins.



FIG. 6I illustrates the next step of the procedure, in which a hemostat having more sharply curved jaws, as illustrated in FIGS. 4A and 4B is employed to create lesion 548. Lesion 548 is created by inserting the jaws of the hemostat illustrated in FIGS. 4A and 4B, one into incision 542, the other into access incision 524, and compressing the atrial septum therebetween. The jaws are arranged so that they define a curved lesion extending along the atrial septum, extending to a point above the fossa ovalis, near but not into the tendon of Todaro. As the atrial septum is not visible in FIG. 6J, lesion 544 should be understood to correspond to the incision illustrated at step M as described in the Doty reference.



FIG. 6J illustrates the next step in the procedure, comprising the removal of left atrial appendage 506 by means of an incision 550. In open chest procedures, this incision might be made by means of a scissors or scalpel. In more limited access surgeries, this incision might be made by means of a thoracoscopically introduced, preferably one capable of simultaneously cutting and stapling the remnant of the right atrial appendage.



FIG. 6K illustrates the next step of the procedure, comprising the creation of lesion 552. Lesion 552 may be created using the curved hemostat illustrated at FIGS. 5A and 5B to create a curved lesion departing from lesion 546 and extending to the opening 550 in the right atrial appendage. As with lesions 543 and 546, the lesion may be produced by inserting one jaw of the hemostat through the incision 542, and compressing the left atrial wall between the jaws of the hemostat. Lesion 552 might also be performed prior to removal of the left atrial appendage, in conjunction with creation of lesions 543 and 546. In some embodiments of the invention, lesion 542 might be replaced by a simple incision extending from the opening 550 of the remnant of the left atrial appendage, and then later repaired by sutures.



FIG. 6L illustrates the next step of the procedure, comprising the creation of lesion 558. Lesion 558 is created using the curved hemostat of FIGS. 5A and 5B, one jaw being inserted through incision 542 and compressing the left atrial wall between the jaws of the hemostat to create a lesion extending from lesion 543 to the mid point 560 of the annulus of the posterior mitral valve. Lesion 558 corresponds to the incision illustrated at step S as described in the Doty reference. Care must be exercised during this incision to prevent damage to the circumflex artery and the coronary sinus. Optionally cryo-ablation may be provided at the mid-point 560 of the posterior mitral valve annulus, by means of a cyro-probe introduced through the opening 550 through the remnant of a left atrial appendage, or through incision 542. In more limited access surgeries, cryo ablation may be provided by means of transvenous cyro-ablation catheter. Cryo-ablation corresponds generally to that illustrated at step J as described in the Doty reference.



FIG. 6M illustrates the final steps of the procedure, comprising closing of the openings 505 and 550 into the remnants of the right and left atrial appendages, respectively, by means of sutures 554 and 556. As noted above, in the event that thoracoscopic surgical implements are employed, these openings may have previously been closed in conjunction with their creation, by means of staples, or otherwise, by means of thoracoscopic surgical tools. In addition, incision 542 is shown as closed by means of sutures 560 as discussed above, in some embodiments, incision 542 may have been replaced by simple puncture incision, which might be closed by means of staple, sutures, or otherwise, applied thoracoscopically. Access in incision 524 is similarly closed at this time.


The hemostats as illustrated in FIGS. 1A through 5B, discussed above, have the general configuration of conventional hemostats, as would be employed in the context of an open chest procedure. In the event that the procedure is adapted to a thoracoscopic procedure, similarly configured hemostat jaws may be employed on thoracoscopically introduced instruments to create the various lesion patterns. It is also envisioned that some modifications to the specific configurations of the disclosed hemostats may be desirable in conjunction with adapting the hemostats to thoracoscopic use or, in conjunction with adapting the hemostat set to other versions of the Maze or Maze type procedures. Such modifications are believed to be within the scope of the invention.


While all of the hemostats disclosed in the present application are preferably provided with R-F electrodes to create elongated lesions, it is believed the invention may also usefully be practiced in conjunction with hemostats employing microwave, heat, cyro-ablation, laser or other ablative techniques to create the various lesions provided by the method. Further, while the hemostats disclosed in the present application are provided with a single elongated electrode extending along each jaw, embodiments in which multiple electrodes arrayed along each jaw are employed are also believed useful in practicing the invention in some cases.


Therefore, the above disclosure should be considered as exemplary, rather than limiting, with regard to the following claims.

Claims
  • 1. A system for treatment of tachyarrhythmias, comprising: a set of bipolar electrosurgical ablation devices, comprising: a first ablation device having first mechanically coupled elongated opposing jaws extending distally with a first straight segment having a fixed first length, the first opposing jaws having first ablation elements extending along the length of the first straight segment of each of the opposing jaws;a second ablation device having second handle members defining a plane of the second ablation device, and second mechanically coupled elongated opposing jaws extending distally with a first curved segment having a fixed first radius of curvature and a second straight segment having a fixed second length, the second straight segment extending distally from the first curved segment, the second opposing jaws having second ablation elements extending along the first curved segment and the second straight segment of each of the second opposing jaws;a third ablation device having third handle members defining a plane of the second ablation device, and third mechanically coupled elongated opposing jaws extending distally with a second curved segment having a fixed second radius of curvature and a third straight segment having a fixed third length, the third straight segment extending distally from the second curved segment, the third opposing jaws having third ablation elements extending along the second curved segment and the third straight segment of each of the third opposing jaws;wherein the second opposing jaws extend out of the plane of the second ablation device and third opposing jaws extend out of the plane of the third ablation device,wherein the second radius of curvature is greater than the first radius of curvature and the first length is greater than the third length which is greater than the second length, andwherein the lengths and the radii of curvature are selected to allow arrangement of the opposing jaws of the first ablation device, the second ablation device and the third ablation device along opposite sides of walls of a patient's atrium such that by applying ablation energy to the walls with the electrodes, lines of lesion corresponding generally to incisions employed in a Maze type procedure may be produced.
  • 2. A system as in claim 1, wherein each of the first opposing jaws, the second opposing jaws and the third opposing jaws contain a lumen for delivery of conductive fluid along each of the first ablation elements, the second ablation elements and the third ablation elements, respectively.
  • 3. A system as in claim 1, further comprising at least one temperature sensor or thermocouple extending along at least one of the first opposing jaws, the second opposing jaws and the third opposing jaws.
  • 4. A system as in claim 1, wherein a distal tip of at least one of the first opposing jaws, the second opposing jaws and the third opposing jaws is sized and shaped to pierce tissue.
  • 5. A system as in claim 4, wherein the distal tip is sharpened.
  • 6. A system as in claim 1 wherein at least one of the first ablation elements, the second ablation elements and the third ablation elements comprises an electrode.
  • 7. A system as in claim 6 wherein the electrode comprises conductive coils.
  • 8. A system as in claim 1 wherein at least one of the first ablation elements, the second ablation elements and the third ablation elements delivers radio frequency energy.
  • 9. A system as in claim 1 wherein at least one of the first ablation elements, the second ablation elements and the third ablation elements comprises a microwave ablating element.
  • 10. A system as in claim 1 wherein at least one of the first ablation elements, the second ablation elements and the third ablation elements comprises a cryo-ablation ablating element.
  • 11. A system as in claim 1 wherein at least one of the first ablation elements, the second ablation elements and the third ablation comprises a laser ablating element.
  • 12. A system as in claim 1 wherein the first ablation device includes first handle members defining a plane of the first ablation device, and the first opposing jaws extend within the plane of the first ablation device.
  • 13. A system as in claim 1 wherein the first ablation device, relative the second and third ablation devices, is particularly configured to provide a lesion on each side of atrial tissue from midway between a superior vena cava and an inferior vena cava to the superior vena cava and to provide a lesion on each side of atrial tissue from midway between the superior vena cava and the inferior vena cava to the inferior vena cava.
  • 14. A system as in claim 1 wherein the second ablation device, relative the first and third ablation devices, is particularly configured to provide a lesion on each side of atrial tissue from midway between a superior vena cava and an inferior vena cava through a left atrial wall posterior to an inter atrial groove near right pulmonary veins.
  • 15. A system as in claim 14 wherein the lesion extends along an atrial septum to a above a fossa ovalis and near but not into a tendon of Todaro.
  • 16. A system as in claim 1 wherein the third ablation device, relative the first and second ablation devices, is particularly configured to provide a lesion on each side of atrial tissue encircling bases of pulmonary veins.
  • 17. A system for treatment of atrial tachyarrhythmias, comprising: a set of bipolar electrosurgical ablation devices, comprising: a first ablation device having first elongated opposing jaws extending distally with a first straight segment having a fixed first length, the first opposing jaws having first ablation elements for applying ablation energy long the first ablation elements extending along the length of the first straight segment of each of the opposing jaws;a second ablation device having second handle members defining a plane of the second ablation device, and second elongated opposing jaws extending distally with a first curved segment having a fixed first radius of curvature and a second straight segment having a fixed second length, the second straight segment extending distally from the first curved segment, the second opposing jaws having second ablation elements for applying ablation energy along the second ablation elements extending along the first curved segment and the second straight segment of each of the second opposing jaws;a third ablation device having third handle members defining a plane of the second ablation device, and third elongated opposing jaws extending distally with a second curved segment having a fixed second radius of curvature and a third straight segment having a fixed third length, the third straight segment extending distally from the second curved segment, the third opposing jaws having third ablation elements for applying ablation energy along the third ablation elements extending along the second curved segment and the third straight segment of each of the third opposing jaws;a pair of magnets extending along respective ones of at least one of the first opposing jaws, the second opposing jaws and the third opposing jaws to attract respective ones of at least the one of the first ablation elements, second ablation elements, and third ablation elements together along an entire elongated length of the respective ablation elements;wherein the second opposing jaws extend out of the plane of the second ablation device and third opposing jaws extend out of the plane of the third ablation device,wherein the second radius of curvature is greater than the first radius of curvature and the first length is greater than the third length which is greater than the second length, andwherein the lengths and the radii of curvature are selected to allow arrangement of the opposing jaws of the first ablation device, the second ablation device and the third ablation device along opposite sides of walls of a patient's atrium such that by applying ablation energy to the walls with the ablation elements, lines of lesion corresponding generally to incisions employed in a Maze type procedure may be produced.
  • 18. A system as in claim 17, wherein at least one of the first ablation elements, the second ablation elements and the third ablation elements comprises a microwave ablating elements.
  • 19. A system as in claim 17, wherein at least one of the first ablation elements, the second ablation elements and the third ablation elements is a cryo-ablation ablating element.
  • 20. A system as in claim 17, wherein at least one of the first ablation elements, the second ablation elements and the third ablation elements is a laser ablating element.
  • 21. A system as in claim 17, wherein each of the first opposing jaws, the second opposing jaws and the third opposing jaws contain a lumen for delivery of conductive fluid along each of the first ablation elements, the second ablation elements and the third ablation elements.
  • 22. A system as in claim 17, wherein at least one of the first ablation elements, the second ablation elements and the third ablation elements comprise elongated conductive coils.
  • 23. A system as in claim 17, further comprising at least one temperature sensor or thermocouple extending along at least one of the first opposing jaws, the second opposing jaws and the third opposing jaws.
  • 24. A system as in claim 17, wherein a distal tip of at least one of the first opposing jaws, the second opposing jaws and the third opposing jaws is sized and shaped to pierce tissue.
  • 25. A system as in claim 24, wherein the distal tip is sharpened.
  • 26. A system as in claim 17 wherein at least one of the first ablation elements, the second ablation elements and the third ablation elements delivers radio frequency energy.
  • 27. A system as in claim 17 wherein the first ablation device includes first handle members defining a plane of the first ablation device, and the first opposing jaws extend out of the plane of the first ablation device.
  • 28. A system as in claim 17 wherein the first ablation device, relative the second and third ablation devices, is particularly configured to provide a first lesion on each side of atrial tissue from midway between a superior vena cava and an inferior vena cava to the superior vena cava and to provide a second lesion on each side of atrial tissue from midway between the superior vena cava and the inferior vena cava to the inferior vena cava; wherein the second ablation device, relative the first and third ablation devices, is particularly configured to provide a third lesion on each side of atrial tissue from midway between a superior vena cava and an inferior vena cava through a left atrial wall posterior to an inter atrial groove near right pulmonary veins; andwherein the third ablation device, relative the first and second ablation devices, is particularly configured to provide a fourth lesion on each side of atrial tissue encircling bases of pulmonary veins.
  • 29. A system as in claim 28 wherein the third lesion extends along an atrial septum to a above a fossa ovalis and near but not into a tendon of Todaro.
  • 30. A system as in claim 17 wherein at least one of the first ablation elements, the second ablation elements and the third ablation comprises an electrode.
RELATED US APPLICATION DATA

This application is a divisional of U.S. patent application Ser. No. 10/015,690, filed Dec. 12, 2001, now U.S. Pat. No. 6,807,968, which claims the benefit of, and incorporated by reference an entirety of, U.S. Application Ser. No. 60/286,953, filed on Apr. 26, 2001.

US Referenced Citations (443)
Number Name Date Kind
2102270 Hyams Dec 1937 A
2275167 Bierman Mar 1942 A
3736936 Basiulis et al. Jun 1973 A
3807403 Stumpf et al. Apr 1974 A
3823575 Parel Jul 1974 A
3823718 Tromovitch Jul 1974 A
3827436 Stumpf et al. Aug 1974 A
3830239 Stumpf Aug 1974 A
3859986 Okada et al. Jan 1975 A
3862627 Hans, Sr. Jan 1975 A
3886945 Stumpf et al. Jun 1975 A
3907339 Stumpf et al. Sep 1975 A
3910277 Zimmer Oct 1975 A
3913581 Ritson et al. Oct 1975 A
3924628 Droegemueller et al. Dec 1975 A
4018227 Wallach Apr 1977 A
4022215 Benson May 1977 A
4061135 Widran et al. Dec 1977 A
4063560 Thomas et al. Dec 1977 A
4072152 Linehan Feb 1978 A
4082096 Benson Apr 1978 A
4207897 Lloyd et al. Jun 1980 A
4248224 Jones Feb 1981 A
4275734 Mitchiner Jun 1981 A
4278090 van Gerven Jul 1981 A
4301802 Poler Nov 1981 A
4377168 Rzasa et al. Mar 1983 A
4519389 Gudkin et al. May 1985 A
4562900 Anderson et al. Jan 1986 A
4598698 Siegmund Jul 1986 A
4601290 Effron et al. Jul 1986 A
4664110 Schanzlin May 1987 A
4671274 Sorochenko Jun 1987 A
4674499 Pao Jun 1987 A
4705038 Sjostrom et al. Nov 1987 A
4736749 Lundback Apr 1988 A
4779611 Grooters et al. Oct 1988 A
4802475 Weshahy Feb 1989 A
4815470 Curtis et al. Mar 1989 A
4872346 Kelly-Fry et al. Oct 1989 A
4916922 Mullens Apr 1990 A
4917095 Fry et al. Apr 1990 A
4936281 Stasz Jun 1990 A
4946460 Merry et al. Aug 1990 A
5013312 Parins et al. May 1991 A
5029574 Shimamura et al. Jul 1991 A
5044165 Linner et al. Sep 1991 A
5078713 Varney Jan 1992 A
5080102 Dory Jan 1992 A
5080660 Buelina Jan 1992 A
5100388 Behl et al. Mar 1992 A
5108390 Potocky et al. Apr 1992 A
5147355 Friedman et al. Sep 1992 A
5178133 Pena Jan 1993 A
5207674 Hamilton May 1993 A
5217860 Fahy et al. Jun 1993 A
5222501 Ideker et al. Jun 1993 A
5224943 Goddard Jul 1993 A
5228923 Hed Jul 1993 A
5231995 Desai Aug 1993 A
5232516 Hed Aug 1993 A
5254116 Baust et al. Oct 1993 A
5263493 Avitall Nov 1993 A
5269291 Carter Dec 1993 A
5275595 Dobak, III Jan 1994 A
5277201 Stern Jan 1994 A
5281213 Milder et al. Jan 1994 A
5281215 Milder Jan 1994 A
5295484 Marcus et al. Mar 1994 A
5309896 Moll et al. May 1994 A
5314466 Stern et al. May 1994 A
5316000 Chapelon et al. May 1994 A
5317878 Bradshaw et al. Jun 1994 A
5318525 West et al. Jun 1994 A
5322520 Milder Jun 1994 A
5323781 Ideker et al. Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5324284 Imran Jun 1994 A
5324286 Fowler Jun 1994 A
5334181 Rubinsky et al. Aug 1994 A
5334193 Nardella Aug 1994 A
5348554 Imran et al. Sep 1994 A
5353783 Nakao et al. Oct 1994 A
5354258 Dory Oct 1994 A
5357956 Nardella Oct 1994 A
5361752 Moll et al. Nov 1994 A
5385148 Lesh et al. Jan 1995 A
5396887 Imran Mar 1995 A
5397304 Truckai Mar 1995 A
5400770 Nakao et al. Mar 1995 A
5400783 Pomeranz et al. Mar 1995 A
5402792 Kimura Apr 1995 A
5403309 Coleman et al. Apr 1995 A
5403311 Abele et al. Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5409483 Campbell et al. Apr 1995 A
5413550 Castel May 1995 A
5421819 Edwards et al. Jun 1995 A
5423807 Milder Jun 1995 A
5423811 Imran et al. Jun 1995 A
5427119 Swartz et al. Jun 1995 A
5431649 Mulier et al. Jul 1995 A
5433708 Nichols et al. Jul 1995 A
5435308 Gallup et al. Jul 1995 A
5435805 Edwards et al. Jul 1995 A
5437651 Todd et al. Aug 1995 A
5441499 Fritzsch Aug 1995 A
5441507 Wilk Aug 1995 A
5443463 Stern et al. Aug 1995 A
5443470 Stern et al. Aug 1995 A
5448994 Iinuma Sep 1995 A
5450843 Moll et al. Sep 1995 A
5452582 Longsworth Sep 1995 A
5452733 Sterman et al. Sep 1995 A
5462545 Wang et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5469853 Law et al. Nov 1995 A
5470308 Edwards et al. Nov 1995 A
5470309 Edwards et al. Nov 1995 A
5472876 Fahy Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5478330 Imran et al. Dec 1995 A
5484400 Edwards et al. Jan 1996 A
5486193 Bourne et al. Jan 1996 A
5487385 Avitall Jan 1996 A
5487757 Truckai et al. Jan 1996 A
5496312 Klicek Mar 1996 A
5496335 Thomason et al. Mar 1996 A
5497774 Swartz et al. Mar 1996 A
5498248 Milder Mar 1996 A
5500012 Brucker et al. Mar 1996 A
5505730 Edwards Apr 1996 A
5516505 McDow May 1996 A
5520682 Baust et al. May 1996 A
5522870 Ben-Zion Jun 1996 A
5536267 Edwards et al. Jul 1996 A
5542915 Edwards et al. Aug 1996 A
5545171 Sharkey et al. Aug 1996 A
5545195 Lennox et al. Aug 1996 A
5545200 West et al. Aug 1996 A
5549661 Kordis et al. Aug 1996 A
5554110 Edwards et al. Sep 1996 A
5555883 Avitall Sep 1996 A
5556377 Rosen et al. Sep 1996 A
5558671 Yates Sep 1996 A
5558673 Edwards et al. Sep 1996 A
5560362 Sliwa, Jr. et al. Oct 1996 A
5562720 Stern et al. Oct 1996 A
5569241 Edwards Oct 1996 A
5571088 Lennox et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5573529 Haak et al. Nov 1996 A
5573532 Chang et al. Nov 1996 A
5575766 Swartz et al. Nov 1996 A
5575788 Baker et al. Nov 1996 A
5575810 Swanson et al. Nov 1996 A
5578007 Imran Nov 1996 A
5582589 Edwards et al. Dec 1996 A
5582609 Swanson et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5588960 Edwards et al. Dec 1996 A
5590657 Cain et al. Jan 1997 A
5591125 Edwards et al. Jan 1997 A
5595183 Swanson et al. Jan 1997 A
5596995 Sherman et al. Jan 1997 A
5599294 Edwards et al. Feb 1997 A
5599295 Rosen et al. Feb 1997 A
5607389 Edwards et al. Mar 1997 A
5607462 Imran Mar 1997 A
5617854 Munsif Apr 1997 A
5630794 Lax et al. May 1997 A
5630837 Crowley May 1997 A
5637090 McGee et al. Jun 1997 A
5643197 Brucker et al. Jul 1997 A
5656029 Imran et al. Aug 1997 A
5658278 Imran et al. Aug 1997 A
5667488 Lundquist et al. Sep 1997 A
5671747 Connor Sep 1997 A
5672153 Lax et al. Sep 1997 A
5673695 McGee et al. Oct 1997 A
5676662 Fleischhacker et al. Oct 1997 A
5676692 Sanghvi et al. Oct 1997 A
5676693 LaFontaine Oct 1997 A
5678550 Bassen et al. Oct 1997 A
5680860 Imran Oct 1997 A
5681277 Edwards et al. Oct 1997 A
5681278 Igo et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5685878 Falwell et al. Nov 1997 A
5687723 Avitall Nov 1997 A
5687737 Branham et al. Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5690611 Swartz et al. Nov 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697925 Taylor Dec 1997 A
5697927 Imran et al. Dec 1997 A
5697928 Walcott et al. Dec 1997 A
5713942 Stern Feb 1998 A
5716389 Walinsky et al. Feb 1998 A
5718241 Ben-Haim et al. Feb 1998 A
5718701 Shai et al. Feb 1998 A
5720718 Rosen et al. Feb 1998 A
5720775 Lanard Feb 1998 A
5722402 Swanson et al. Mar 1998 A
5730074 Peter Mar 1998 A
5730127 Avitall Mar 1998 A
5730704 Avitall Mar 1998 A
5733280 Avitall Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5735290 Sterman et al. Apr 1998 A
5749846 Edwards et al. May 1998 A
5755760 Maguire et al. May 1998 A
5769846 Edwards et al. Jun 1998 A
5782828 Chen et al. Jul 1998 A
5785706 Bednarek Jul 1998 A
5788636 Curley Aug 1998 A
5792140 Tu et al. Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5800428 Nelson et al. Sep 1998 A
5800482 Pomeranz et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5827216 Igo et al. Oct 1998 A
5836947 Fleischman et al. Nov 1998 A
5840030 Ferek-Petric et al. Nov 1998 A
5844349 Oakley et al. Dec 1998 A
5846187 Wells et al. Dec 1998 A
5846191 Wells et al. Dec 1998 A
5849011 Jones et al. Dec 1998 A
5849028 Chen Dec 1998 A
5871481 Kannenberg et al. Feb 1999 A
5871523 Fleischman et al. Feb 1999 A
5871525 Edwards et al. Feb 1999 A
5873845 Cline et al. Feb 1999 A
5873877 McGaffigan et al. Feb 1999 A
5876399 Chia et al. Mar 1999 A
5879295 Li et al. Mar 1999 A
5879296 Ockuly et al. Mar 1999 A
5881732 Sung et al. Mar 1999 A
5882346 Pomeranz et al. Mar 1999 A
5885278 Fleischman Mar 1999 A
5893848 Negus et al. Apr 1999 A
5895417 Pomeranz et al. Apr 1999 A
5897553 Mulier Apr 1999 A
5897554 Chia et al. Apr 1999 A
5899898 Arless et al. May 1999 A
5899899 Arless et al. May 1999 A
5902289 Swartz et al. May 1999 A
5904711 Flom et al. May 1999 A
5906580 Kline-Schoder et al. May 1999 A
5906587 Zimmon May 1999 A
5906606 Chee et al. May 1999 A
5908029 Knudson et al. Jun 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5916214 Cosio et al. Jun 1999 A
5921924 Avitall Jul 1999 A
5921982 Lesh et al. Jul 1999 A
5927284 Borst et al. Jul 1999 A
5928191 Houser et al. Jul 1999 A
5931810 Grabek Aug 1999 A
5931848 Saadat Aug 1999 A
5954661 Greenspon et al. Sep 1999 A
5957922 Imran Sep 1999 A
5964727 Edwards et al. Oct 1999 A
5964759 Yamanashi et al. Oct 1999 A
5971980 Sherman Oct 1999 A
5971983 Lesh Oct 1999 A
5993447 Blewett et al. Nov 1999 A
6004269 Crowley et al. Dec 1999 A
6007499 Martin et al. Dec 1999 A
6012457 Lesh Jan 2000 A
6016811 Knopp et al. Jan 2000 A
6022334 Edwards et al. Feb 2000 A
6032077 Pomeranz Feb 2000 A
6042556 Beach et al. Mar 2000 A
6045550 Simpson et al. Apr 2000 A
6056745 Panescu et al. May 2000 A
6063081 Mulier May 2000 A
6071279 Whayne et al. Jun 2000 A
6088894 Oakley Jul 2000 A
6090084 Hassett et al. Jul 2000 A
6096037 Mulier et al. Aug 2000 A
6102886 Lundquist et al. Aug 2000 A
6113592 Taylor Sep 2000 A
6117101 Diederich et al. Sep 2000 A
6120496 Whayne et al. Sep 2000 A
6129726 Edwards et al. Oct 2000 A
6133592 Kishimoto et al. Oct 2000 A
6142944 Li et al. Nov 2000 A
6142993 Whayne et al. Nov 2000 A
6152920 Thompson et al. Nov 2000 A
6159207 Yoon Dec 2000 A
6161543 Cox et al. Dec 2000 A
6165174 Jacobs et al. Dec 2000 A
6187003 Buysse et al. Feb 2001 B1
6193714 McGaffigan et al. Feb 2001 B1
6206847 Edwards et al. Mar 2001 B1
6217528 Koblish et al. Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6231518 Grabek et al. May 2001 B1
6235024 Tu May 2001 B1
6237605 Vaska et al. May 2001 B1
6238347 Nix et al. May 2001 B1
6238393 Mulier May 2001 B1
6245061 Panescu et al. Jun 2001 B1
6245064 Lesh et al. Jun 2001 B1
6245065 Panescu et al. Jun 2001 B1
6251092 Qin et al. Jun 2001 B1
6251128 Knopp et al. Jun 2001 B1
6270471 Hechel et al. Aug 2001 B1
6293943 Panescu et al. Sep 2001 B1
6296619 Brisken et al. Oct 2001 B1
6302880 Schaer Oct 2001 B1
6311692 Vaska et al. Nov 2001 B1
6312383 Lizzi et al. Nov 2001 B1
6314962 Vaska et al. Nov 2001 B1
6314963 Vaska et al. Nov 2001 B1
6325797 Stewart et al. Dec 2001 B1
6328736 Mulier Dec 2001 B1
6332881 Carner et al. Dec 2001 B1
6358248 Mulier Mar 2002 B1
6361531 Hissong Mar 2002 B1
6364876 Erb et al. Apr 2002 B1
6368275 Sliwa et al. Apr 2002 B1
6371955 Fuimaono et al. Apr 2002 B1
6383151 Diederich et al. May 2002 B1
6385472 Hall et al. May 2002 B1
6398792 O'Connor Jun 2002 B1
6409722 Hoey Jun 2002 B1
6413254 Hissong et al. Jul 2002 B1
6419648 Vitek et al. Jul 2002 B1
6419653 Edwards et al. Jul 2002 B2
6425867 Vaezy et al. Jul 2002 B1
6430426 Avitall Aug 2002 B2
6440130 Mulier Aug 2002 B1
6443952 Mulier Sep 2002 B1
6447507 Bednarek et al. Sep 2002 B1
6461314 Pant et al. Oct 2002 B1
6461956 Patterson Oct 2002 B1
6464661 Edwards et al. Oct 2002 B2
6464700 Koblish et al. Oct 2002 B1
6471697 Lesh Oct 2002 B1
6471698 Edwards et al. Oct 2002 B1
6474340 Vaska et al. Nov 2002 B1
6475216 Mulier Nov 2002 B2
6477396 Mest et al. Nov 2002 B1
6484727 Vaska et al. Nov 2002 B1
6488680 Francischelli Dec 2002 B1
6502575 Jacobs et al. Jan 2003 B1
6514250 Jahns Feb 2003 B1
6517536 Hooven et al. Feb 2003 B2
6527767 Wang et al. Mar 2003 B2
6537248 Mulier Mar 2003 B2
6537272 Hoey Mar 2003 B2
6551300 McGaffigan Apr 2003 B1
6558382 Jahns May 2003 B2
5697536 Eggers et al. Jun 2003 C1
6575956 Brisken et al. Jun 2003 B1
6584360 Francischelli Jun 2003 B2
6585732 Mulier Jul 2003 B2
6605084 Acker et al. Aug 2003 B2
6607529 Jones et al. Aug 2003 B1
6610054 Edwards et al. Aug 2003 B1
6610055 Swanson et al. Aug 2003 B1
6610060 Mulier Aug 2003 B2
6613048 Mulier Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6645199 Jenkins et al. Nov 2003 B1
6648883 Francischelli Nov 2003 B2
6656175 Francischelli Dec 2003 B2
6663627 Francischelli Dec 2003 B2
6692450 Coleman Feb 2004 B1
6692491 Phan Feb 2004 B1
6699240 Francischelli Mar 2004 B2
6702811 Stewart et al. Mar 2004 B2
6706038 Francischelli Mar 2004 B2
6706039 Mulier Mar 2004 B2
6716211 Mulier Apr 2004 B2
6730079 Lovewell May 2004 B2
6736810 Hoey May 2004 B2
6755827 Mulier Jun 2004 B2
6764487 Mulier Jul 2004 B2
6773433 Stewart et al. Aug 2004 B2
6776780 Mulier Aug 2004 B2
6807968 Francischelli Oct 2004 B2
6814712 Edwards et al. Nov 2004 B1
6827715 Francischelli Dec 2004 B2
6849073 Hoey Feb 2005 B2
6852091 Edwards et al. Feb 2005 B2
6855141 Lovewell Feb 2005 B2
6858028 Mulier Feb 2005 B2
6887238 Jahns May 2005 B2
6899711 Stewart et al. May 2005 B2
6911019 Mulier Jun 2005 B2
6916318 Francischelli Jul 2005 B2
6936046 Hissong Aug 2005 B2
6949097 Stewart et al. Sep 2005 B2
6949098 Mulier Sep 2005 B2
6960205 Jahns Nov 2005 B2
6962589 Mulier Nov 2005 B2
7041095 Wang et al. May 2006 B2
7094235 Francischelli Aug 2006 B2
7166105 Mulier et al. Jan 2007 B2
7201731 Lundquist et al. Apr 2007 B1
20030045872 Jacobs Mar 2003 A1
20030073991 Francischelli Apr 2003 A1
20030144656 Ocel Jul 2003 A1
20030191462 Jacobs Oct 2003 A1
20030216724 Jahns Nov 2003 A1
20040015106 Coleman Jan 2004 A1
20040015219 Francischelli Jan 2004 A1
20040044340 Francischelli Mar 2004 A1
20040049179 Francischelli Mar 2004 A1
20040078069 Francischelli Apr 2004 A1
20040082948 Stewart et al. Apr 2004 A1
20040087940 Jahns May 2004 A1
20040092926 Hoey May 2004 A1
20040138621 Jahns Jul 2004 A1
20040138656 Francischelli Jul 2004 A1
20040143260 Francischelli Jul 2004 A1
20040186465 Francischelli Sep 2004 A1
20040215183 Hoey Oct 2004 A1
20040220560 Briscoe Nov 2004 A1
20040236322 Mulier Nov 2004 A1
20040267326 Ocel Dec 2004 A1
20050010095 Stewart et al. Jan 2005 A1
20050010203 Edwards et al. Jan 2005 A1
20050033280 Francischelli Feb 2005 A1
20050084804 Truskett et al. Apr 2005 A1
20050090815 Francischelli Apr 2005 A1
20050143729 Francischelli Jun 2005 A1
20050165392 Francischelli Jul 2005 A1
20050209564 Bonner Sep 2005 A1
20050222562 Lovewell Oct 2005 A1
20050267454 Hissong Dec 2005 A1
20060009756 Francischelli Jan 2006 A1
20060009759 Chrisitian Jan 2006 A1
20060020263 Rothstein et al. Jan 2006 A1
20060020271 Stewart et al. Jan 2006 A1
20060036236 Rothstein et al. Feb 2006 A1
20060047278 Christian et al. Mar 2006 A1
20060195082 Francischelli Aug 2006 A1
Foreign Referenced Citations (9)
Number Date Country
916 360 May 1999 EP
1 095 627 May 2001 EP
9725917 Jul 1997 WO
WO 9912488 Mar 1999 WO
9959486 Nov 1999 WO
WO 9959486 Nov 1999 WO
WO 0172234 Oct 2001 WO
0180755 Nov 2001 WO
WO 0180724 Nov 2001 WO
Non-Patent Literature Citations (44)
Entry
U.S. Appl. No. 60/200,072, Apr. 27, 2000, Hooven.
U.S. Appl. No. 60/286,953, Apr. 26, 2001, Francischelli.
Chitwood, “Will C. Sealy, MD: The Father of Arrhythmia Surgery—The Story of the Fisherman with a Fast Pulse,” Annals of Thoracic Surgery 58:1228-1239, 1994.
Gallagher et al., “Cryosurgical Ablation of Accessory Atrioventrical Connections: A Method for Correction of the Pre-excitation Syndrome,” Circulation 55(3): 471-479, 1977.
Sealy, “Direct Surgical Treatment of Arrhythmias: The Last Frontier in Surgical Cardiology,” Chest 75(5): 536-537, 1979.
Sealy, “The Evolution of the Surgical Methods for Interruption of Right Free Wall Kent Bundles,” The Annals of Thoracic Surgery 36(1): 29-36, 1983.
Guiraudon et al., “Surgical Repair of Wolff-Parkinson-White Syndrome: A New Closed-Heart Techique,” The Annals of Thoracic Surgery 37(1): 67-71, 1984.
Klein et al., “Surgical Correction of the Wolff-Parkinson-White Syndrome in the Closed Heart Using Cryosurgery: A Simplified Approach,” JACC 3(2): 405-409, 1984.
Randall et al., “Local Epicardial Chemical Ablation of Vagal Input to Sino-Atrial and Atrioventricular Regions of the Canine Heart,” Journal of the Autonomic Nervous System 11:145-159, 1984.
Guiraudon et al., “Surgical Ablation of Posterior Septal Accessory Pathways in the Wolf-Parkinson-White Syndrome by a Closed Heart Technique,” Journal Thoracic Cardiovascular Surgery 92:406-413, 1986.
Gallagher et al., “Surgical Treatment of Arrhythmias,” The American Journal of Cardiology 61:27A-44A, 1988.
Mahomed et al., “Surgical Division of Wolff-Parkinson-White Pathways Utilizing the Closed-Heart Technique: A 2-Year Experience in 47 Patients,” The Annals of Thoracic Surgery 45(5): 495-504, 1988.
Cox et al., Surgery for Atrial Fibrillation; Seminars in Thoracic and Cardiovascular Surgery , vol. 1, No. 1 (Jul. 1989) pp. 67-73.
Bredikis and Bredikis; Surgery of Tachyarrhythmia: Intracardiac Closed Heart Cryoablation; PACE, vol. 13, pp. 1980-1984.
McCarthy et al., “Combined Treatment of Mitral Regurgitation and Atrial Fibrillation with Valvuloplasty and the Maze Procedure,” The American Journal of Cardiology 71: 483-486, 1993.
Yamauchi et al. “Use of Intraoperative Mapping to Optimize Surgical Ablation of Atrial Flutter,” The Annals of Thoracic Surgery 56: 337-342, 1993.
Graffigna et al., “Surgical Treatment of Wolff-Parkinson-White Syndrome: Epicardial Approach Without the Use of Cardiopulmonary Bypass,” Journal of Cardiac Surgery 8: 108-116, 1993.
Siefert et al., “Radiofrequency Maze Ablation for Atrial Fibrillation,” Circulation 90(4): I-594.
Surgical treatment of atrial fibrillation: a review; Europace (2004) 5, S20-S29.
Elvan et al., “Radiofrequency Catheter Ablation of the Atria Reduces Inducibility and Duration of Atrial Fibrillation in Dog,” Circulation 91: 2235-2244, 1995.
Cox et al., “Modification of the Maze Procedure for Atrial Flutter and Atrial Fibrillation. I. Rational and Surgical Results,” The Journal of Thoracic Cardiovascular Surgery 110: 473-484, 1995.
Cox, “The Maze III Procedure for Treatment of Atrial Fibrillation,” Sabiston DC, ed Atlas of Cardiothoracic Surgery, Philadelphia: WB Saunders: 460-475, 1994.
Sueda et al., “Simple Left Atrial Procedure for Chronic Atrial Fibrillation Associated with Mitral Valve Disease,” The Annals of Thoracic Surgery 62(6): 1796-1800, 1996.
Tsui et al., “Maze 3 for Atrial Fibrillation: Two Cuts Too Few?” PACE 17: 2163-2166, 1994.
Kosakai et al., “Cox Maze Procedure for Chronic Atrial Fibrillation Associated with Mitral Valve Disease,” The Journal of Thoracic Cardiovascular Surgery 108: 1049-1055, 1994.
Cox et al., “The Surgical Treatment of Atrial Fibrillation, IV Surgical Technique,” J of Thorac Cardiovasc Surg, 1991: 101: 584-593.
Nardella, “Radio Frequency Energy and Impedance Feedback,” SPIE vol. 1068, Catheter Based Sensing and Imaging Technology (1989).
Avitall et. al., “A Thoracoscopic Approach to Ablate Atrial Fibrillation Via Linear Radiofrequency Lesion Generation on the Epicardium of Both Atria,” PACE, Apr. 1996;19(Part II):626,#241.
Sie et al., “Radiofrequency Ablation of Atrial Fibrillation in Patients Undergoing Mitral Valve Surgery. First Experience,” Circulation (Nov. 1996) 96:450,I-675,#3946.
Sie et al., “Radiofrequency Ablation of Atrial Fibrillation in Patients Undergoing Valve Surgery,” Circulation (Nov. 1997) 84:I450,#2519.
Jais et al., “Catheter Ablation for Paroxysmal Atrial Fibrillation: High Success Rates with Ablation in the Left Atrium,” Circulation (Nov. 1996) 94:I-675,#3946.
Cox, “Evolving Applications of the Maze Procedure for Atrial Fibrillation,” Ann Thorac Surg, 1993;55:578-580.
Cox et al. “Five-Year Experience with the Maze Procedure for Atrial Fibrillation,” Ann Thorac Surg, 1993; 56:814-824.
Avitall et al., “New Monitoring Criteria for Transmural Ablation of Atrial Tissues,” Circulation, 1996;94(Supp 1):I-493, #2889.
Cox et al., “An 8 1/2 Year Clinical Experience with Surgery for Atrial Fibrillation,” Annals of Surgery, 1996;224(3):267-275.
Haissaguerre et al., “Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation in Humans: Elaboration of a procedure based on electrophysiological data,” Nonpharmacological Management of Atrial Fibrillation, 1997 pp. 257-279.
Haissaguerre et al., “Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, 1996;7(12):1132-1144.
Haissaguerre et al., “Role of Catheter Ablation for Atrial Fibrillation,” Current Opinion in Cardiology, 1997;12:18-23.
Kawaguchi et al., “Risks and Benefits of Combined Maze Procedure for Atrial Fibrillation Associated with Organic Heart Disease,” JACC, 1996;28(4):985-990.
Cox, et al., “Perinodal cryosurgery for atrioventricular node reentry tachycardia in 23 patients,” Journal of Thoracic and Cardiovascular Surgery, 99:3, Mar. 1990, pp. 440-450.
Cox, “Anatomic-Electrophysiologic Basis for the Surgical Treatment of Refractory Ischemic Ventricular Tachycardia,” Annals of Surgery, Aug. 1983; 198:2;119-129.
Williams, et al., “Left atrial isolation,” J Thorac Cardiovasc Surg; 1980; 80: 373-380.
Scheinman, “Catheter-based Techniques for Cure of Cardiac Arrhythmias,” Advances in Cardiovascular Medicine, 1996, ISSN 1075-5527, pp. 93-100.
Sueda et al., “Efficacy of a Simple Left Atrial Procedure for Chronic Atrial Fibrillation in Mitral Valve Operations,” Ann Thorac Surg, 1997;63:1070-1075.
Related Publications (1)
Number Date Country
20050033280 A1 Feb 2005 US
Provisional Applications (1)
Number Date Country
60286953 Apr 2001 US
Divisions (1)
Number Date Country
Parent 10015690 Dec 2001 US
Child 10923073 US